ImmunityBio, Inc. IBRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$632.8M-388% | -$61.96M-4.7% | -$67.27M+21.5% | -$92.57M+31.2% | -$129.67M+3.3% | ||
| $4.38M+14.4% | $3.87M-6.6% | $3.95M-11.3% | $3.88M-11.9% | $3.83M-15.9% | ||
| $8.17M-14.3% | $8.75M-3.2% | $8.88M+18.5% | $9.65M+0.1% | $9.54M+15.4% | ||
| $700K-95.2% | $10.56M— | $9.89M+215% | $5.1M+393% | $14.67M— | ||
| $4.99M+2,798% | $7.89M+25.0% | $63K-57.1% | -$1.8M-200% | $172K— | ||
| $3.9M-39.4% | —— | -$1.39M+84.4% | —— | $6.44M+49.3% | ||
| $3.14M+124% | $1.93M+191% | $5.47M-12.2% | $8.72M— | -$12.93M-45.0% | ||
| $1.05M+1,152% | —— | —— | -$1.23M-2,404% | $84K+164% | ||
| $16K-93.4% | $82K— | $35K-5.4% | $210K+500% | $243K+228% | ||
| -$180K-1,536% | -$28K+96.1% | $43K-12.2% | -$4K-180% | -$11K-134% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $4M+363% | —— | ||
| -$75.36M+12.3% | -$70.38M+17.3% | -$68.91M+30.2% | -$79.75M+20.5% | -$85.91M+19.7% | ||
| $1.78M+58.4% | $903K-57.2% | $741K-73.5% | $1.08M+49.3% | $1.12M-11.1% | ||
| $139.09M+138,993% | $45.63M+649% | $180.59M— | $15.06M-82.4% | $100K-99.8% | ||
| $79.38M+1,384% | $59.55M+230% | —— | —— | $5.35M-58.9% | ||
| -$31.65M-867% | —— | -$181.36M— | -$16.14M+68.7% | $4.13M+112% | ||
| $61K— | —— | —— | —— | $0— | ||
| $868K— | —— | —— | —— | $0— | ||
| $971K+341% | $1.61M-28.1% | —— | —— | $220K— | ||
| $13K— | $12K— | $12K-45.5% | $4K-81.0% | $0-100% | ||
| $6.99M+482% | $590K-26.5% | $151K-49.5% | $322K-35.1% | $1.2M-68.9% | ||
| $223.93M+22,903% | $54.89M-48.7% | $173.52M+1,014% | $172.81M+16.1% | -$982K-110% | ||
| $122K+1,320% | $5K+171% | —— | $76K— | -$10K+74.4% | ||
| $117.04M+241% | —— | -$76.81M-323% | —— | -$82.77M+37.5% | ||
| $20.12M+29.0% | $18.59M-10.9% | $18.27M-22.4% | $18.87M-21.3% | $15.59M-34.8% | ||
| $1.53M+2,835% | $1.7M+7,000% | $978K+68.6% | $11K-97.2% | $52K-89.4% | ||
| -$1.11M+80.1% | —— | -$289K+82.1% | -$1.93M+90.9% | -$5.58M-305% | ||
| $3.9M-39.4% | —— | -$1.39M+84.4% | —— | $6.44M+49.3% | ||
| $570K+1,018% | —— | $501K+3.5% | —— | $51K+132% | ||
| $3.14M+124% | $1.93M+191% | $5.47M-12.2% | $8.72M— | -$12.93M-45.0% | ||
| $8.32M-37.3% | $8.63M-16.1% | $9.31M-11.4% | $10.02M+8.8% | $13.27M+65.7% | ||
| $62K0.0% | $63K+105% | $63K+1.6% | $62K0.0% | $62K-1.6% | ||
| $1.43M— | —— | —— | —— | $0— | ||
| —— | $3.5M— | $3.5M— | $3.5M— | $3.5M— | ||
| $7.44M— | —— | —— | —— | $0— | ||
| $10M— | $0-100% | —— | —— | $0-100% | ||
| $11K— | $372K— | —— | —— | $0— | ||
| $79.38M+1,384% | $59.55M+230% | —— | —— | $5.35M-58.9% | ||
| $13K— | $12K— | $12K-45.5% | $4K-81.0% | $0-100% | ||
| $102.23M— | —— | —— | —— | $0— | ||
| $61K— | —— | —— | —— | $0— | ||
| $53.54M— | $0— | $0-100% | $0-100% | $0-100% | ||
| $868K— | —— | —— | —— | $0— | ||
| $1.41M+27.0% | $792K— | —— | $197K-87.8% | $1.11M-19.7% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $54K— | —— | —— | —— | $0— | ||
| $122K+1,320% | $5K+171% | —— | $76K— | -$10K+74.4% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $295.41M+65,840% | -$30.74M-216% | -$14.91M+52.4% | -$3.89M-120% | $448K-75.1% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $75M— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $1.72M— | $1.38M— | $0-100% | $4.53M— | $0— | ||
| $16.38M+447% | $1.61M-28.1% | —— | —— | $3M— | ||
| $136K— | $65K-91.9% | $110K— | $118K— | $0— | ||
| -$180K-1,536% | —— | $43K-12.2% | -$4K-180% | -$11K-134% | ||
| $35.33M— | —— | —— | —— | $0— | ||
| -$77.14M+11.4% | -$71.28M+18.3% | -$69.65M+31.4% | -$80.83M+20.0% | -$87.03M+19.6% | ||
| -$77.14M+11.4% | -$71.28M+18.3% | -$69.65M+31.4% | -$80.83M+20.0% | -$87.03M+19.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ImmunityBio, Inc. generate?
- ImmunityBio, Inc. (IBRX) generated -$294.4M in operating cash flow over the trailing twelve months.
- What is ImmunityBio, Inc.'s free cash flow?
- After $4.5M of capital expenditures, ImmunityBio, Inc.'s free cash flow was -$298.9M over the trailing twelve months, up 20.7% year over year.
- Where does ImmunityBio, Inc.'s cash flow data come from?
- Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
